Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States

Circ Heart Fail. 2022 Mar;15(3):e009099. doi: 10.1161/CIRCHEARTFAILURE.121.009099. Epub 2021 Dec 10.

Authors

Rahul Aggarwal¹, Muthiah Vaduganathan², Nicholas Chiu¹, Deepak L Bhatt²

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (R.A., N.C.).
² Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.V., D.L.B.).

PMID: 34886682
PMCID: PMC8920018
DOI: 10.1161/CIRCHEARTFAILURE.121.009099

No abstract available

Keywords: Medicare; heart disease; insurance; kidney; pharmacy.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Health Expenditures
Heart Failure*
Humans
Hypoglycemic Agents / therapeutic use
United States

Substances

Hypoglycemic Agents